Herpes Simplex Virus 1 Infection Models

Herpes simplex virus 1 (HSV-1) is one of the most prevalent pathogens in the world. More than 3.7 billion people under the age of 50 – roughly two thirds of the global population in that age group – carry it, almost all of them for life. The virus establishes lifelong latency in sensory nerve ganglia after primary infection and reactivates periodically, driven by stress, illness, or immune suppression, producing the recurrent outbreaks that define the infection.

HSV-1 is transmitted primarily through oral contact and is the classic cause of orolabial herpes (“cold sores”), but it is increasingly responsible for genital herpes as well. Most infections are asymptomatic or mild in immunocompetent people; in the immunocompromised, in neonates, and at immune-privileged sites such as the eye and the brain, it causes severe disease — keratitis, encephalitis, and disseminated infection — that can be blinding or fatal. There is no cure, no licensed vaccine, and an emerging problem of antiviral-resistant infection in the most vulnerable patients.

TransPharm Preclinical Solutions evaluates candidates against HSV-1 in a validated cutaneous infection model and produces the virological and clinical data an antiviral program needs.

The scientific problem in an HSV-1 study is matching the challenge to the question a candidate is designed to answer. The scratch model reproduces acute cutaneous HSV-1 infection and the nerve-mediated zosteriform spread that follows it — a relevant setting for topical antivirals, systemic agents, and candidates aimed at controlling acute skin disease or viral spread. What the model doesn’t reproduce is latency or the CNS disease that drives the worst morbidity, so candidates aimed at reactivation or encephalitis require separate considerations.

A susceptible reference strain establishes baseline virological activity, while an acyclovir-resistant challenge isolate is the appropriate strain for a program positioned against resistant disease, which is increasingly where the unmet need lies in immunocompromised patients. TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized HSV-1 isolates to a program’s specifications.

Every study parameter – challenge strain, host species and strain, route of administration, comparator agents, and dosing schedule – is configurable to the scientific question. Because HSV-1 is a virus rather than a bacterium, the core readout is virological and clinical: the extent and severity of lesion spread, scored by the zosteriform spread clinical scoring system rather than by colony-forming units.

The following are available as add-ons to any study:

• Pharmacokinetic profiling and PK/PD analysis
• Blood chemistry
• Additional tissue harvests
• Histopathology

The scratch model uses dermal abrasion to disrupt the epidermal barrier and establish cutaneous HSV-1 infection, then follows the virus’s characteristic spread through sensory nerve fibers. The dorsal skin is abraded with sandpaper to remove the outermost epidermal layer, and animals receive a topical inoculation at the abraded site.

After inoculation, HSV-1 spreads from the skin into sensory nerve endings, travels to the dorsal root ganglia, and then spreads anterogradely back to the skin in a belt-like (zosteriform) pattern — the same nerve-mediated spread that characterizes shingles-like disease. Test article may be administered by topical application, oral gavage, or subcutaneous, intraperitoneal, or intravenous injection, supporting both topically and systemically delivered candidates.

The primary endpoint is clinical scoring of zosteriform spread, assessed by trained observers on a standardized scale that captures the severity and distribution of skin lesions; histopathology is available to confirm tissue-level findings. Validated in mice.

The cornerstone of HSV-1 treatment is acyclovir and its oral prodrug valacyclovir, with famciclovir and penciclovir as alternatives; all are nucleoside analogues that require activation by the viral thymidine kinase (TK) before they can block the viral DNA polymerase. That dependence on TK is also the principal route to resistance. Mutations in the UL23 gene, which encodes TK, either abolish its activity or alter its substrate specificity, preventing drug activation. In 95% of resistant isolates the mechanism is TK-based, and TK mutations also confer cross-resistance to penciclovir, famciclovir, and brivudine, since all require the same activation step. Mutations in UL30, which encodes the viral DNA polymerase, account for most of the remaining resistant isolates and can confer resistance to foscarnet as well.

In immunocompetent people, acyclovir-resistant HSV-1 is rare – below one percent. In immunocompromised patients it is a genuine and growing problem: resistance is found in roughly five percent of immunocompromised patients overall and in up to a quarter of bone marrow transplant recipients who receive prolonged antiviral therapy. For these patients, foscarnet and cidofovir – drugs that do not require TK activation – are the main alternatives, but both are toxic and less convenient than the nucleoside analogues they replace. The absence of a licensed vaccine for HSV-1, despite decades of development efforts, leaves antiviral therapy as the only tool, which is why resistance at the TK and DNA polymerase level is the central concern for next-generation antiviral programs.